Should You Continue to Hold EW Stock in Your Portfolio?

Edwards Lifesciences (EW), market cap ~$48.3bn and a Zacks Rank #3, is positioned for continued top-line growth driven by its Surgical Structural Heart franchise (RESILIA/INSPIRIS/KONECT), a 10.6% y/y TAVR rebound including FDA approval of SAPIEN 3 for asymptomatic AS, and a fast-growing TMTT business (Q3 sales +53% driven by PASCAL and EVOQUE), with surgical sales +5.3% in Q3 2025; the company has beaten EPS estimates in the last four quarters (avg surprise 8.9%) and the stock is up ~13.4% year-over-year. However, significant margin headwinds—COGS rose 31.3% in Q3 amid inflation, supply-chain and staffing constraints—and ongoing patent litigation pose material risks to profitability and execution. Consensus 2025 estimates sit at $2.59 EPS and ~$6.03bn revenue (+1% y/y), leaving a narrative of strong product-led growth tempered by cost pressure and legal uncertainty.

Analysis

Edwards Lifesciences is demonstrating clear product-led growth: Surgical Structural Heart sales rose 5.3% in Q3 2025 driven by RESILIA/INSPIRIS/KONECT adoption, TAVR revenue grew 10.6% year-over-year with FDA approval of SAPIEN 3 for asymptomatic AS, and Transcatheter Mitral & Tricuspid Therapies (TMTT) sales surged 53% as PASCAL and EVOQUE scale globally. The company has beaten EPS estimates in each of the trailing four quarters with an average surprise of 8.89% and the stock is up ~13.4% year-over-year versus an industry decline of 2.1%, supporting the view of durable demand across franchises for a $48.33 billion market-cap company.

Material margin and execution risks temper the top-line strength: cost of goods sold jumped 31.3% in Q3 amid inflation, supply-chain constraints and hospital staffing shortages, and management cited ongoing litigation over intellectual property that could affect results and reputation. Consensus 2025 estimates are modest at $2.59 EPS and $6.03 billion revenue (roughly +1% y/y), consistent with a story of strong product growth offset by margin pressure and legal uncertainty.

Near-term catalysts include further commercial rollout of EVOQUE/PASCAL sites, uptake from expanded TAVR indications, and regulatory approvals; near-term risks to monitor are sequential COGS/margin trends, any litigation settlements or judgments, and guidance revisions, which will materially influence the stock's re-rating given the constrained consensus growth outlook.

Key Decisions for Investors

• Consider maintaining a constructive but size-constrained position to capture sustained product momentum from TAVR and TMTT (10.6% and 53% y/y growth in Q3) while recognizing valuation and execution risk,
• Make margin exposure the primary monitoring trigger: trim or hedge positions if sequential COGS and operating margin trends do not improve from the Q3 COGS increase of 31.3%,
• Treat upcoming legal outcomes and near‑term guidance as binary catalysts—use options protection or reduce exposure ahead of major litigation or guidance events and add on confirmed improvements in margin guidance or continued beat-and-raise results